-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KUsmJTjY6m31k7isLKqaWN8UPpFKpEeLmJezU4Nl16ApYW9Cjk4A90JGIarfYZe+ cg+ZFZNvn1YJla661upTpg== 0001193125-10-285674.txt : 20101221 0001193125-10-285674.hdr.sgml : 20101221 20101221170407 ACCESSION NUMBER: 0001193125-10-285674 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101216 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20101221 DATE AS OF CHANGE: 20101221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIX BIOMEDIX INC CENTRAL INDEX KEY: 0000831749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 912099117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-20897 FILM NUMBER: 101266399 BUSINESS ADDRESS: STREET 1: 22118 20TH AVE SE STREET 2: SUITE 204 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425 402 8400 MAIL ADDRESS: STREET 1: 22118 20TH AVE SE STREET 2: SUITE 204 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: CARTEL ACQUISITIONS INC DATE OF NAME CHANGE: 19890718 FORMER COMPANY: FORMER CONFORMED NAME: CARIBBEAN ACQUISTIONS INC DATE OF NAME CHANGE: 19880725 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2010

 

 

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   033-20897-D   91-2099117

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

22118 20th Avenue S.E., Suite 204

Bothell, Washington 98021

(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

On December 16, 2010, Helix BioMedix, Inc. (the “Company”) entered into an International Distribution Agreement with Dermopia Inc. (“Dermopia”), pursuant to which Dermopia was appointed as an exclusive distributor of certain of the Company’s proprietary skin care, wound care and anti-microbial products in certain cosmetic and medical industry markets in China, Japan and South Korea (the “Dermopia Distribution Agreement”). The Dermopia Distribution Agreement contains initial and annual minimum purchase requirements and expires March 31, 2015 unless renewed for subsequent one-year terms upon mutual consent of the parties thereto. Dermopia is the successor to RubyDerm Bio Inc. (“RubyDerm Bio”), with which the Company was a party to an International Distribution Agreement dated March 3, 2010 (the “RubyDerm Bio Distribution Agreement”), and the terms and conditions of the Dermopia Distribution Agreement are substantially identical to those of the RubyDerm Bio Distribution Agreement.

 

Item 1.02 Termination of a Material Definitive Agreement.

On November 18, 2010, the Company delivered a notice of termination to RubyDerm Bio terminating the RubyDerm Bio Distribution Agreement pursuant to the terms and conditions thereof. See Item 1.01 above.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      HELIX BIOMEDIX, INC.
Dated: December 21, 2010     By:  

/s/ R. Stephen Beatty

      R. Stephen Beatty
      President and Chief Executive Officer

 

3

-----END PRIVACY-ENHANCED MESSAGE-----